載入中
HKSEHealthcareDrug Manufacturers - Specialty & Generic
最新資料
HK$0.165
−HK$0.009 · -5.17%
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
最新資料
HK$0.165
−HK$0.009 · -5.17%
盤中時間採用HKT。市場資料可能有所延遲。
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
日內區間
目前HK$0.165
52週區間
目前HK$0.165
盤中時間採用HKT。市場資料可能有所延遲。
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of China. Its comprehensive product portfolio encompasses IVD reagents designed for assessing male and female fertility, detecting parasite antibodies, and identifying the Epstein-Barr virus. Additionally, the company provides auxiliary reproductive supplies and equipment, alongside a range of healthcare products and nutritional supplements marketed under its 'Nutronic' brand, which are sold through both digital and physical platforms. Products are distributed directly to hospitals and medical institutions, as well as through a network of third-party distributors. The company was founded in 1992 and maintains its headquarters in Wan Chai, Hong Kong.
日內區間
目前HK$0.165
52週區間
目前HK$0.165
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（CNY） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 2828.2萬 CNY | 2535.9萬 CNY | 2462.9萬 CNY | 2533萬 CNY | 2612.7萬 CNY |
| 銷貨成本 | 1051.3萬 CNY | 828.7萬 CNY | 853.6萬 CNY | 841.6萬 CNY | 967.1萬 CNY |
| 毛利 | 1776.9萬 CNY | 1707.2萬 CNY | 1609.3萬 CNY | 1691.4萬 CNY | 1645.6萬 CNY |
| 研究與開發 | 392.5萬 CNY | 282.5萬 CNY | 255.3萬 CNY | 248.3萬 CNY | 243.7萬 CNY |
| 銷售、一般及管理費用 | 2147萬 CNY | 1925.8萬 CNY | 1849.1萬 CNY | 1875.4萬 CNY | 1769.9萬 CNY |
| 營業費用 | 2633.6萬 CNY | 2208.3萬 CNY | 2348.4萬 CNY | 2200.4萬 CNY | 2103.4萬 CNY |
| 利息收入 | 31.56萬 CNY | 51.2萬 CNY | 40.4萬 CNY | 40.9萬 CNY | 17.9萬 CNY |
| 利息支出 | 23.96萬 CNY | 8.6萬 CNY | 5.3萬 CNY | 5.5萬 CNY | 10.2萬 CNY |
| 折舊和攤銷 | 371.6萬 CNY | 333.4萬 CNY | 317.9萬 CNY | 314萬 CNY | 294.9萬 CNY |
| 營業利益 | −781萬 CNY | −568.8萬 CNY | −739.1萬 CNY | −509萬 CNY | −432.95萬 CNY |
| 淨利 | −500.6萬 CNY | −415.8萬 CNY | −578.2萬 CNY | −307.5萬 CNY | −422萬 CNY |
公司資料更新於 2026年10月10日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
